Kedrion Biopharma
Leyla Arienzo is a Regulatory Affairs Associate and International Product Owner at Kedrion Biopharma, with prior experience as a Regulatory Affairs Consultant at JSB Solutions and as an intern at Sanofi. At Kedrion Biopharma, Leyla manages life cycle activities for pharmaceutical products focusing on the international and EU markets. Notable responsibilities include quality variations, renewals, and new registrations, as well as preparing documentation for health authority submissions. At JSB Solutions, Leyla contributed significantly to the Rare Disease Unit, conducting gap analyses and engaging with local partners. Leyla's educational background includes a degree in Sustainable Industrial Pharmaceutical Biotechnology from Università di Siena and a degree in Pharmaceutical Chemistry from The Manchester Metropolitan University.
This person is not in any teams
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.